WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

WCC# 59: Pilot Study of Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01144442
• Other study ID #: 2009LS114
• Secondary ID: WCC# 591003M7887
• Status: Terminated
• Phase: N/A
• Start date: July 27, 2010
• Est. completion date: May 1, 2015

Study information

• Verified date: July 2019
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, pilot study in patients with a diagnosis of recurrent ovarian, fallopian tube or primary peritoneal carcinoma who have undergone standard cytoreductive surgery following by adjuvant chemotherapy. It is expected that this first surgery was optimal - as defined as no residual tumor > or = 1 centimeter. Patient has clinical evidence of a first recurrence. The patient undergoes surgery and isotonic normal saline (perfusate) heated and administered into the abdomen, followed by hyperthermic intraperitoneal chemotherapy infusion (HIPC) administering carboplatin (chemotherapy). Six weeks after surgery patients will receive adjuvant chemotherapy with Paclitaxel and Carboplatin for 6 cycles.

Description:

OBJECTIVES

• The primary objectives are

• to determine the clinical response of hyperthermic intraperitoneal chemotherapy (HIPC) in patients at the time of first clinical recurrence of ovarian, fallopian tube, or primary peritoneal carcinoma

• to determine the feasibility of delivering HIPC in a recurrent setting.

• Secondary objectives are

• to determine disease free survival (DFS) and overall survival (OS),

• to determine treatment related changes in quality of life (QOL)

• to monitor the toxicities and complications associated with HIPC.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: May 1, 2015
• Est. primary completion date: September 25, 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 16 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients should have a histological diagnosis of primary ovarian, fallopian tube, or primary peritoneal carcinoma and have undergone chemotherapy according.

• Initial attempted cytoreductive surgery must have been performed by gynecologic oncologist with strict adherence to GOG surgical manual.

• End result of first surgery must have been optimal cytoreduction as defined as no residual tumor = 1cm.

• Patients should have clinical evidence of first recurrence. Two fold elevations in CA125 or measurable tumor on CT scan constitute adequate evidence of recurrent disease.

• Patients with the following primary tumor epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, adenocarcinoma (non-specific) NOS, mixed epithelial carcinoma.

• Patients must have platin sensitive disease, defined as a recurrence occurring greater than 6 months from cessation of original treatment.

• Patients must have a performance status of 0, 1, 2.

• Patients must have adequate bone marrow function as defined by an absolute neutrophil count (ANC) =1500, platelet count = 100,000, and a hemoglobin of greater than 10g/dl.

• Patients must have adequate renal function as defined by serum creatinine = 1.5 mg/dl.

• Patients must have adequate hepatic function as defined by bilirubin = 1.5 times normal levels, alkaline phosphatase and SGOT = 3 times normal levels.

• Patients who have signed an Institutional Review Board (IRB) approved informed consent.

• Female patients 16-90 years of age.

• Patients must be deemed medically able to undergo a secondary surgical procedure.

Patient eligibility for systemic chemotherapy following HIPC:

• Patients must have successfully completed HIPC within 6 weeks of first prescribed intravenous carboplatin and taxane cycle.

• Patients must have a performance status of 0, 1, or 2.

• Patients must have adequate bone marrow function as defined as an ANC = 1500, platelet count = 100,000, and a hemoglobin of greater than 10g/dl.

• Patients must have adequate renal function as defined by serum creatinine = 1.5 mg/dl.

• Patients must have adequate hepatic function as defined by bilirubin = 1.5 times normal levels, alkaline phosphatase and SGOT = 3 times normal levels.

• Patients who have signed an IRB approved informed consent.

Exclusion Criteria:

• Patients with known recurrent disease outside the abdominal cavity.

• Patients with low malignant tumor at primary diagnosis as determined by pathologic review.

• Patients with platin resistant disease as define as recurrence or progressive disease prior to 6 months from completion of primary therapy.

• Patients with any evidence of another malignancy within the last 5 years with the exception of non-melanoma skin cancer.

• Patients with evidence of concurrent septicemia, severe infection, renal failure, or acute hepatitis.

• Patients with history of grade 3 or greater gastrointestinal bleeding.

• Patients with a GOG performance score of 3 or 4.

• Patients deemed medically unable to tolerate the HIPC procedure by care giving physician.

• Patients with known allergy to platinum chemotherapy agents.

• Patients with equal to or greater than grade 2 neuropathy.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Fever
• Ovarian Cancer
• Ovarian Neoplasms
• Peritoneal Carcinoma
• Recurrence

Intervention

Drug:
• Hyperthermic intraperitoneal chemotherapy with Carboplatin
Carboplatin at a dose of 1000mg/m^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.

Other:
• Isotonic saline (perfusate)
The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.

Procedure:
• Surgery
The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus. If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach.

Drug:
• Carboplatin
The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
• Paclitaxel
The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.

Locations

Country	Name	City	State
United States	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Response	We will summarize clinical response as the proportion of patients with complete response. Complete response will be defined as normalization of CA125. - After 6 cycles of Second Line Adjuvant Chemotherapy.	After 6 cycles of Paclitaxel & Carboplatin (Week 21 up to 27)
Primary	Feasibility of HIPC in Recurrent Disease Setting	We will determine feasibility based on the proportion of patients who complete 6 prescribed cycles of second line chemotherapy after undergoing the HIPC procedure.	6 months
Secondary	Quality of Life Measurements	The quality of life measurements (version 4 of the FACT-O questionnaire) will be summed over each subscale and overall and comparisons will be made using t-tests at distinct visits.	Baseline, 6 Weeks Post Surgery, Every 3 Weeks Up to Week 27
Secondary	Progression-free Survival	Disease progression will be defined as time from surgery to first of either an increase in CA125 from post-treatment value (to a value greater than 100 or doubling of nadir CA125 levels) or new/increasing measurable disease by CT scan as defined by RECIST criteria, (secondary recurrence) or censored at date of last contact for patients still alive and who have no progressed or recurred (from date of surgery to disease progression).	Up to 5 Years (intended)
Secondary	Overall Survival	Overall survival will be defined as time from date of surgery to date of death or censored at the date of last documented contact for patients still alive.	Up to 5 Years